VivoSeq
Ophthalmology

Macular Edema

0

Pipeline Programs↗

4

Active Trials↗

8

Companies Involved↗

Macular Edema is an early-stage landscape with 0 programs across 8 companies. The most active players are Boehringer Ingelheim, Eli Lilly, AbbVie.

Intelligence

Pipeline Metrics

Competitive Density

16/100

Pipeline Velocity

11/100

Mech. Concentration

N/A

Completion Rate

71/100

Attrition Rate

21/100

Competition

Competitive Landscape

Bubble size = clinical trials

Approved
Phase 3
Phase 2
Phase 1
Preclinical

Key Players

Top Companies Companies ranked by the number of pipeline programs they run for this disease.

Boehringer Ingelheim logo

Boehringer Ingelheim

1 program

Phase 2Eli Lilly logo

Eli Lilly

1 program

Phase 2AbbVie logo

AbbVie

0 programs

PreclinicalNovartis logo

Novartis

0 programs

PreclinicalMerck & Co. logo

Merck & Co.

0 programs

PreclinicalE

EyeBiotech Ltd.

0 programs

Preclinical

Pipeline

Programs by Phase

No pipeline programs currently tracked for this disease.

Analysis

Trial Status

43

clinical trials

Completed22 · 51%
Unknown status8 · 19%
Terminated7 · 16%
Recruiting3 · 7%
Withdrawn2 · 5%
Not yet recruiting1 · 2%

Clinical Trials

Trial Activity

43 trials

A Dose-masked Study of Intravitreal EYE103 in Participants With NVAMD or Macular Edema Following BRVO
Recruiting·EEyeBiotech Ltd.·Phase 2·NCT07205887·160 enrolled
Safety, Tolerability and Efficacy of Intravitreal KIO-104 in Patients With Macular Edema
Recruiting·KKiora Pharmaceuticals, Inc.·Phase 2·NCT06825702·28 enrolled
A Randomised, Double-masked, Placebo-controlled Trial to Evaluate the Efficacy, Safety, and Tolerability of Oral BI 1815368 in Participants With Centre-involved Diabetic Macular Edema for 48 Weeks of Treatment (THULITE)
Recruiting·Boehringer Ingelheim logoBoehringer Ingelheim·Phase 2·NCT06962839·300 enrolled
Study of CU06-1004 in Patients With Daibetic Macular Edema
Not yet recruiting·CCuracle Co., Ltd.·Phase 2·NCT07459829·156 enrolled
A Retrospective Chart Review of OZURDEX® in Patients With Macular Edema
Completed·AbbVie logoAbbVie·N/A·NCT01805323·101 enrolled
Intravitreal Faricimab in Patients With Refractory Macular Edema
Completed·UUniversity of Baghdad·Phase 2·NCT07093385·43 enrolled
Research Study in Patients With Persistent Macular Edema
Completed·AbbVie logoAbbVie·Phase 2·NCT00035906·315 enrolled
Nepafenac Once Daily for Macular Edema - Study 1
Completed·AAlcon Research·Phase 3·NCT01853072·881 enrolled
Intravitreal v. Sub-tenon Injections of Triamcinolone Acetonide for Macular Edema in Retinal Disorders
Completed·National Eye Institute (NEI)·Phase 1·NCT00101764·120 enrolled
Bevacizumab Versus Ranibizumab in Treatment of Macular Edema From Vein Occlusion
Completed·BBarnes Retina Institute·N/A·NCT01428388·150 enrolled
Ozurdex for Macular Edema Post Membrane Peeling
Completed·RRetina Specialists, PC·Phase 2/3·NCT01273727·35 enrolled
Evaluation of a Treat and Extend Regimen of Intravitreal Aflibercept for Macular Edema Secondary to CRVO
Completed·Bayer logoBayer·Phase 4·NCT02800642·162 enrolled
A Study to Evaluate the Safety, Tolerability and Pharmacokinetics of IVT MHU650 in Macular Edema Patients
Completed·Novartis logoNovartis·Phase 1·NCT04635800·21 enrolled
A Study to Assess the Safety, Tolerability, Pharmacokinetics and Pharmacodynamic Activity of Intravitreal LKA651 in Patients With Macular Edema
Completed·Novartis logoNovartis·Phase 1·NCT02867735·28 enrolled
Effect of Choline Fenofibrate (SLV348) on Macular Edema
Completed·—·Phase 2·NCT00683176·110 enrolled
Page 1 of 3

Data sources: ClinicalTrials.gov (NIH) · OpenFDA (FDA) · ChEMBL (EMBL-EBI) · Open Targets (EBI/Sanger) · MedlinePlus (NIH) · PubMed (NIH) · SEC EDGAR (SEC)